Although initial results with these new inhibitors showed partial responses of about 6% in patients with PIK3CA (mutant) breast cancer, no responses had been detected in patients with PIK3CAI (wild-type) tumors (Janku et al., 2015). The gene discussed is PIK3CA; the disease is breast cancer.